HUE056603T2 - HIV integráz gátló hatású policiklusos karbamoilpiridon-származék - Google Patents

HIV integráz gátló hatású policiklusos karbamoilpiridon-származék

Info

Publication number
HUE056603T2
HUE056603T2 HUE18166621A HUE18166621A HUE056603T2 HU E056603 T2 HUE056603 T2 HU E056603T2 HU E18166621 A HUE18166621 A HU E18166621A HU E18166621 A HUE18166621 A HU E18166621A HU E056603 T2 HUE056603 T2 HU E056603T2
Authority
HU
Hungary
Prior art keywords
inhibitory activity
hiv integrase
integrase inhibitory
polycyclic carbamoylpyridone
carbamoylpyridone derivative
Prior art date
Application number
HUE18166621A
Other languages
English (en)
Hungarian (hu)
Inventor
Brian Alvin Johns
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Viiv Healthcare Co
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE056603(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co, Shionogi & Co filed Critical Viiv Healthcare Co
Publication of HUE056603T2 publication Critical patent/HUE056603T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE18166621A 2005-04-28 2006-04-28 HIV integráz gátló hatású policiklusos karbamoilpiridon-származék HUE056603T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27

Publications (1)

Publication Number Publication Date
HUE056603T2 true HUE056603T2 (hu) 2022-02-28

Family

ID=37215098

Family Applications (6)

Application Number Title Priority Date Filing Date
HUE18166621A HUE056603T2 (hu) 2005-04-28 2006-04-28 HIV integráz gátló hatású policiklusos karbamoilpiridon-származék
HUE17195280 HUE044978T2 (hu) 2005-04-28 2006-04-28 HIV integráz gátló aktivitású policiklusos karbamoilpiridon származék
HUE16154531A HUE037795T2 (hu) 2005-04-28 2006-04-28 HIV-integráz gátló hatással rendelkezõ policiklusos karbamoilpiridon származék
HUS1400039C HUS1400039I1 (hu) 2005-04-28 2014-07-09 HIV Integráz inhibitor hatással rendelkezõ policiklusos karbamoilpiridon-származékok
HUS2100023C HUS2100023I1 (hu) 2005-04-28 2021-06-14 HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok
HUS2100022C HUS2100022I1 (hu) 2005-04-28 2021-06-14 HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok

Family Applications After (5)

Application Number Title Priority Date Filing Date
HUE17195280 HUE044978T2 (hu) 2005-04-28 2006-04-28 HIV integráz gátló aktivitású policiklusos karbamoilpiridon származék
HUE16154531A HUE037795T2 (hu) 2005-04-28 2006-04-28 HIV-integráz gátló hatással rendelkezõ policiklusos karbamoilpiridon származék
HUS1400039C HUS1400039I1 (hu) 2005-04-28 2014-07-09 HIV Integráz inhibitor hatással rendelkezõ policiklusos karbamoilpiridon-származékok
HUS2100023C HUS2100023I1 (hu) 2005-04-28 2021-06-14 HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok
HUS2100022C HUS2100022I1 (hu) 2005-04-28 2021-06-14 HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok

Country Status (30)

Country Link
US (22) US8129385B2 (enExample)
EP (9) EP3284519A1 (enExample)
JP (2) JP4295353B2 (enExample)
KR (4) KR101363875B1 (enExample)
AU (1) AU2006239177B8 (enExample)
BE (1) BE2021C519I2 (enExample)
BR (1) BRPI0610030B8 (enExample)
CA (1) CA2606282C (enExample)
CY (7) CY1115151T1 (enExample)
DK (6) DK3187225T3 (enExample)
EA (1) EA014162B1 (enExample)
ES (7) ES2667868T5 (enExample)
FI (1) FIC20210017I1 (enExample)
FR (1) FR14C0041I2 (enExample)
HK (2) HK1249742A1 (enExample)
HU (6) HUE056603T2 (enExample)
IL (4) IL186555A (enExample)
LT (5) LT3045206T (enExample)
LU (2) LU92446I2 (enExample)
MA (1) MA29460B1 (enExample)
MX (2) MX302718B (enExample)
NL (2) NL300676I2 (enExample)
NO (5) NO339525B1 (enExample)
NZ (1) NZ562339A (enExample)
PL (5) PL1874117T3 (enExample)
PT (5) PT3284520T (enExample)
SI (6) SI3284520T1 (enExample)
TW (1) TWI378931B (enExample)
VN (1) VN34404A1 (enExample)
WO (1) WO2006116764A1 (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697377B1 (en) 2003-12-24 2011-01-26 Biota Scientific Management Pty. Ltd. Polycyclic agents for the treatment of respiratory syncytial virus infections
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
PT3284520T (pt) * 2005-04-28 2019-09-10 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
EP1937678B1 (en) 2005-10-04 2011-07-27 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705312C (en) * 2007-11-15 2013-06-25 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2330902B1 (en) * 2008-07-25 2012-11-14 GlaxoSmithKline LLC Chemical compounds
EP2320909B8 (en) * 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320908B9 (en) * 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
JP5572168B2 (ja) * 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
EP3210603A1 (en) * 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
KR101663222B1 (ko) * 2008-12-11 2016-10-06 시오노기세야쿠 가부시키가이샤 말톨 에테르 방법 및 중간체
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TR201808501T4 (tr) 2009-06-15 2018-07-23 Shionogi & Co Sübstitüe polisiklik karbamoilpiridon türevi.
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
KR20120087916A (ko) 2009-10-13 2012-08-07 엘랑코 애니멀 헬쓰 아일랜드 리미티드 마크로시클릭 인테그라제 억제제
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
CA2967453C (en) * 2010-01-27 2018-07-17 Viiv Healthcare Company Combinations for use in the inhibition of hiv-1
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
NZ601847A (en) * 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US8716293B2 (en) 2010-04-02 2014-05-06 Janssen R&D Ireland Macrocyclic integrase inhibitors
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
SG187683A1 (en) 2010-08-05 2013-03-28 Shionogi & Co Process for preparing compound having hiv integrase inhibitory activity
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
BR112013006722B1 (pt) 2010-09-24 2020-11-03 Shionogi & Co., Ltd profármaco de derivado de carbamoilpiridona policíclica substituída
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
AU2012321762A1 (en) 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
HUE035069T2 (en) 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
EA037633B1 (ru) * 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
TW201431859A (zh) * 2012-12-27 2014-08-16 Japan Tobacco Inc 經取代之螺吡啶並［１，２－ａ］吡□衍生物及該衍生物作爲ＨＩＶ整合酶抑制劑之醫藥用途
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2993155T3 (en) 2013-03-15 2024-12-23 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (enExample) 2013-07-12 2018-07-21
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
SG10201911662YA (en) 2014-02-07 2020-02-27 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN107056813B (zh) * 2014-03-19 2019-07-30 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enExample) 2014-03-20 2015-09-25 Cipla Ltd
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) * 2014-06-20 2018-06-23
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
EP3253767A2 (en) 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Processes for the preparation of dolute-gravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
TR201905009T4 (tr) * 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
ES2857906T3 (es) * 2015-04-28 2021-09-29 Shionogi & Co Derivado de piridona policíclica contra la influenza y profármaco del mismo
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
US10597404B2 (en) 2015-08-19 2020-03-24 Laurus Labs Ltd. Polymorphs of dolutegravir and salts thereof
EA201890654A1 (ru) 2015-11-09 2018-10-31 Джилид Сайэнс, Инк. Терапевтические композиции для лечения вируса иммунодефицита человека
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
HUE072191T2 (hu) 2015-12-04 2025-10-28 Global Blood Therapeutics Inc A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
US10696636B2 (en) 2015-12-21 2020-06-30 Lupin Limited Process for the preparation of HIV integrase inhibitors
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
ES3035041T3 (en) 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
EP3496724B8 (en) * 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018057408A1 (en) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
RU2749043C2 (ru) 2016-12-02 2021-06-03 Мерк Шарп И Доум Корп. Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
EP3363802B1 (en) * 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
EP3583107B1 (en) 2017-02-16 2020-11-18 Sandoz AG Crystalline form of cabotegravir sodium
EP3655106A4 (en) * 2017-07-18 2021-04-21 VIIV Healthcare Company COMBINED INGREDIENTS THERAPY
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
JP6924839B2 (ja) 2017-10-06 2021-08-25 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TWI880373B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
EP3805221A4 (en) * 2018-05-31 2022-01-05 Shionogi & Co., Ltd POLYCYCLIC PYRIDONE DERIVATIVE
CR20230571A (es) 2018-05-31 2024-01-22 Shionogi & Co DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644)
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
IL320867A (en) 2018-10-22 2025-07-01 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
CN113874079B (zh) 2019-03-22 2024-11-08 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
KR20220112771A (ko) 2019-12-09 2022-08-11 비이브 헬쓰케어 컴퍼니 카보테그라비르를 포함하는 제약 조성물
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230321089A1 (en) 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
US20250296988A1 (en) 2020-12-07 2025-09-25 Viiv Healthcare Company Combination therapy
DK4196479T5 (da) 2021-01-19 2025-01-02 Gilead Sciences Inc Substituerede pyridotriazinforbindelser og anvendelser deraf
EP4389745A4 (en) * 2021-06-03 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co Ltd PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
JP2024542776A (ja) 2021-12-03 2024-11-15 ヴィーブ、ヘルスケア、カンパニー （ｒ）－３－アミノブタン－１－オールの合成方法
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024153203A1 (en) * 2023-01-18 2024-07-25 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
KR20010033405A (ko) 1997-12-22 2001-04-25 로렌스 티.마이즌 헬더. 4-히드록시퀴놀린-3-카르복스아미드 및 히드라지드항바이러스제
AU2001262732A1 (en) † 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
ATE481401T1 (de) 2002-12-27 2010-10-15 Angeletti P Ist Richerche Bio Tetrahydro-4h-pyridoä1,2-aüpyrimidine und verwandte verbindungen verwendbar als hiv integrase hemmer
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
JP4859676B2 (ja) 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
JP2007528394A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
CA2564372C (en) 2004-05-07 2011-10-11 Merck & Co., Inc. Hiv integrase inhibitors
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
PT3284520T (pt) * 2005-04-28 2019-09-10 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
JP2009503081A (ja) 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
WO2007049675A1 (ja) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

Also Published As

Publication number Publication date
DK1874117T3 (da) 2013-09-23
KR101848819B1 (ko) 2018-04-16
US20190284208A1 (en) 2019-09-19
US20090318421A1 (en) 2009-12-24
US9273065B2 (en) 2016-03-01
CY2021016I2 (el) 2021-12-31
EP3284520A1 (en) 2018-02-21
CY1122052T1 (el) 2020-10-14
ES2667868T3 (es) 2018-05-14
IL225207A (en) 2017-11-30
EP1874117B1 (en) 2013-08-28
BRPI0610030B8 (pt) 2022-01-11
PT1874117E (pt) 2013-10-17
US20130172559A1 (en) 2013-07-04
LTC2465580I2 (enExample) 2022-10-10
SI3187225T1 (sl) 2022-04-29
MX302718B (es) 2012-08-27
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
HK1249742A1 (en) 2018-11-09
AU2006239177B8 (en) 2012-02-16
US20170224695A1 (en) 2017-08-10
HUE037795T2 (hu) 2018-09-28
CY2014024I1 (el) 2015-12-09
DK2465580T3 (en) 2014-03-10
KR20160003889A (ko) 2016-01-11
NO2021018I1 (no) 2021-05-10
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (en) 2008-01-09
NL301109I2 (nl) 2021-09-15
FR14C0041I2 (fr) 2015-11-13
NO2017010I2 (no) 2017-03-27
PL1874117T3 (pl) 2014-01-31
KR101504998B1 (ko) 2015-03-23
CY1124601T1 (el) 2022-07-22
DK3284520T3 (da) 2019-09-16
US20170260203A1 (en) 2017-09-14
KR20140097438A (ko) 2014-08-06
CY2021016I1 (el) 2021-10-15
JP2009079058A (ja) 2009-04-16
LT3284520T (lt) 2019-09-25
PL2465580T3 (pl) 2014-05-30
BRPI0610030A2 (pt) 2011-10-11
LUC00210I2 (enExample) 2022-10-07
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
US20120115875A1 (en) 2012-05-10
NL300676I2 (enExample) 2016-10-11
LTPA2021512I1 (enExample) 2021-07-12
PL3284520T3 (pl) 2020-01-31
TWI378931B (en) 2012-12-11
HUE044978T2 (hu) 2019-11-28
ES2906792T3 (es) 2022-04-20
US9051337B2 (en) 2015-06-09
EA014162B1 (ru) 2010-10-29
HK1172282A1 (en) 2013-04-19
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
NZ562339A (en) 2011-01-28
PT3372281T (pt) 2021-10-14
NO340111B1 (no) 2017-03-13
US20170145033A1 (en) 2017-05-25
EP3284519A1 (en) 2018-02-21
EP3187225A1 (en) 2017-07-05
NO20075165L (no) 2007-11-22
US20200339598A1 (en) 2020-10-29
US20170253616A1 (en) 2017-09-07
KR101363875B1 (ko) 2014-02-21
CY2014024I2 (el) 2025-05-09
IL186555A (en) 2016-10-31
CA2606282A1 (en) 2006-11-02
US20140200209A1 (en) 2014-07-17
US20170267693A1 (en) 2017-09-21
BRPI0610030B1 (pt) 2020-09-15
EP3372281A1 (en) 2018-09-12
US8129385B2 (en) 2012-03-06
DK3187225T3 (da) 2022-02-28
MX2007013351A (es) 2008-01-21
JP2008540343A (ja) 2008-11-20
EP3187225B1 (en) 2022-01-05
EP3284519A8 (en) 2018-04-18
SI1874117T1 (sl) 2014-01-31
CY1115151T1 (el) 2015-12-09
US20150232479A1 (en) 2015-08-20
NL301109I1 (nl) 2021-09-15
PL3045206T3 (pl) 2018-08-31
ES2567197T3 (es) 2016-04-20
CA2606282C (en) 2016-04-26
US20170224694A1 (en) 2017-08-10
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
EP2527007B1 (en) 2016-03-30
EP3187226A1 (en) 2017-07-05
US20170209454A1 (en) 2017-07-27
TW200716635A (en) 2007-05-01
EP3045206B2 (en) 2023-02-15
JP4295353B2 (ja) 2009-07-15
HUS2100023I1 (hu) 2021-07-28
HUS1400039I1 (hu) 2016-08-29
EP2465580A1 (en) 2012-06-20
EP3284520B1 (en) 2019-06-05
US8778943B2 (en) 2014-07-15
PL3372281T3 (pl) 2021-12-27
DK3372281T3 (da) 2021-09-27
SI2465580T1 (sl) 2014-04-30
ES2667868T5 (es) 2023-06-01
IL215788A0 (en) 2011-12-29
ES2437268T3 (es) 2014-01-09
EP1874117B8 (en) 2014-03-12
US20240279238A1 (en) 2024-08-22
LT3045206T (lt) 2018-06-11
MA29460B1 (fr) 2008-05-02
IL186555A0 (en) 2008-01-20
SI3284520T1 (sl) 2019-10-30
ES2892304T3 (es) 2022-02-03
SI3372281T1 (sl) 2021-11-30
PT3045206T (pt) 2018-07-05
LU92446I2 (fr) 2015-10-29
AU2006239177B2 (en) 2011-10-20
LTPA2014021I1 (lt) 2014-07-25
EP3372281B1 (en) 2021-07-07
EP3045206A1 (en) 2016-07-20
EP2465580B1 (en) 2013-12-18
IL225206A (en) 2017-11-30
FR14C0041I1 (enExample) 2014-06-27
KR101580310B1 (ko) 2016-01-04
PT2465580E (pt) 2014-02-25
HK1251191A1 (en) 2019-01-25
BE2021C519I2 (enExample) 2025-12-10
ES2446324T3 (es) 2014-03-07
US11267823B2 (en) 2022-03-08
CY1120345T1 (el) 2019-07-10
US20160304535A1 (en) 2016-10-20
FIC20210017I1 (fi) 2021-06-10
NO2017010I1 (no) 2017-03-27
US20170029438A1 (en) 2017-02-02
WO2006116764A1 (en) 2006-11-02
SI3045206T1 (en) 2018-07-31
CY1116331T1 (el) 2017-02-08
HUS2100022I1 (hu) 2021-07-28
PT3284520T (pt) 2019-09-10
MX312216B (en) 2013-08-12
KR20130133061A (ko) 2013-12-05
EP2527007A1 (en) 2012-11-28
LTC1874117I2 (lt) 2025-03-25
NO2023042I1 (no) 2023-11-08
US20160207939A1 (en) 2016-07-21
EA200702080A1 (ru) 2008-04-28
US20160137666A1 (en) 2016-05-19
EP1874117A4 (en) 2009-12-30
ES2743531T3 (es) 2020-02-19
EP3045206B1 (en) 2018-03-28
US20220213121A1 (en) 2022-07-07
US20190152990A1 (en) 2019-05-23
US8410103B2 (en) 2013-04-02
NO339525B1 (no) 2016-12-27

Similar Documents

Publication Publication Date Title
IL186555A0 (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1790638A4 (en) CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
SI1948666T1 (sl) Hiv integrazni inhibitorji
EP1756069A4 (en) HIV INTEGRASE INHIBITORS
IL177189A0 (en) Hiv integrase inhibitors
IL177858A0 (en) Hiv integrase inhibitors
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
IL189939A0 (en) Inhibitors of the hiv integrase enzyme
EP1910356A4 (en) HIV integrase
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE
EP1910355A4 (en) HIV integrase
ZA200606956B (en) HIV integrase inhibitors